Leonard Bell Net Worth is167.8 $Million
Company Name: Alexion Pharmaceuticals
Company Type: Public company
Traded As: {{NASDAQ/ALXN/NASDAQ-100 component}}
Foundation: 1992
Location City: Cheshire, Connecticut, Connecticut, United States
Key People: Max E. Link (Chairman),
Industry: Pharmaceutical industry
Products: Eculizumab
Revenue: United States Dollar 783.431 million (2011)url
Operating Income: US$ 230.826 million (2011) net income
Assets: US$ 1.395 billion (2011) equity
Num Employees: 792 (December 2010) Homepage: [http://www.alxn.com/ alxn.com]
Company Type: Public company
Traded As: {{NASDAQ/ALXN/NASDAQ-100 component}}
Foundation: 1992
Location City: Cheshire, Connecticut, Connecticut, United States
Key People: Max E. Link (Chairman),
Industry: Pharmaceutical industry
Products: Eculizumab
Revenue: United States Dollar 783.431 million (2011)url
Operating Income: US$ 230.826 million (2011) net income
Assets: US$ 1.395 billion (2011) equity
Num Employees: 792 (December 2010) Homepage: [http://www.alxn.com/ alxn.com]
Alexion Pharmaceuticals (NASDAQ: ALXN) is the original developer and distributor of Soliris, a drug used in treating the rare disorders Hemolytic-uremic syndrome and Paroxysmal nocturnal hemoglobinuria (PNH).
The company is also involved in research regarding the immune system and how it can be stopped from attacking healthy tissue (done by inhibiting terminal complements).
Soliris, the company's sole marketed drug, has been approved for use in the EU and Japan however its availability in other places like the USA and Canada is limited due to marketing restrictions and lack of ensured access (in Canada access to the drug is mostly through private clinics though groups like the Canadian Association of PNH Patients are lobbying to change that).
In 2011 50% of the increase in assets came from cash and cash equivalents, the value of which has since gone down since part of it was spent on acquiring Enobia. In the last quarter R&D spending was higher due to expansion of development programs while net sales of Soliris increased 45% to $227.6 million on account of new international patients with paroxysmal nocturnal hemoglobinuria.
Founded in 1992 in New Haven, Connecticut (at a place called Science Park). In 2000 it paid USD 41 million in Alexion stock for Proliferon Inc., a San Diego, California based development-stage biopharmaceutical firm that has since been renamed Alexion Antibody Technologies Inc. Alexion CEO at the time (Leonard Bell) cited Proliferon's ability to produce an 'unlimited amount of antibodies' as the reason for the acquisition (also referred to as a merger). At the time Proliferon's annual revenue was about $2.5 million and its assets were valued at $2.1 million Also that year Alexion moved its headquarters from New Haven to Cheshire, Connecticut.
On April 4, 2011 Alexion became a member of the Nasdaq-100, a group composed of the 100 largest non-financial stocks traded on the Nasdaq; with a market value of USD 8.5 billion it replaced Ge
The company is also involved in research regarding the immune system and how it can be stopped from attacking healthy tissue (done by inhibiting terminal complements).
Soliris, the company's sole marketed drug, has been approved for use in the EU and Japan however its availability in other places like the USA and Canada is limited due to marketing restrictions and lack of ensured access (in Canada access to the drug is mostly through private clinics though groups like the Canadian Association of PNH Patients are lobbying to change that).
In 2011 50% of the increase in assets came from cash and cash equivalents, the value of which has since gone down since part of it was spent on acquiring Enobia. In the last quarter R&D spending was higher due to expansion of development programs while net sales of Soliris increased 45% to $227.6 million on account of new international patients with paroxysmal nocturnal hemoglobinuria.
Founded in 1992 in New Haven, Connecticut (at a place called Science Park). In 2000 it paid USD 41 million in Alexion stock for Proliferon Inc., a San Diego, California based development-stage biopharmaceutical firm that has since been renamed Alexion Antibody Technologies Inc. Alexion CEO at the time (Leonard Bell) cited Proliferon's ability to produce an 'unlimited amount of antibodies' as the reason for the acquisition (also referred to as a merger). At the time Proliferon's annual revenue was about $2.5 million and its assets were valued at $2.1 million Also that year Alexion moved its headquarters from New Haven to Cheshire, Connecticut.
On April 4, 2011 Alexion became a member of the Nasdaq-100, a group composed of the 100 largest non-financial stocks traded on the Nasdaq; with a market value of USD 8.5 billion it replaced Ge
(Visited 68 times, 1 visits today)
